# A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls

> **NCT01663740** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 59 (actual)

## Conditions studied

- Cytomegalovirus Infections

## Interventions

- **DRUG:** Valganciclovir

## Key facts

- **NCT ID:** NCT01663740
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-30
- **Primary completion:** 2015-09-29
- **Final completion:** 2016-12-30
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2018-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01663740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01663740, "A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT01663740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*